DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019
SUMMARY
DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Acinetobacter Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Bacterial Infections, Klebsiella pneumoniae Infections, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Mycobacterium Infections, Pseudomonas aeruginosa Infections and Tuberculosis.
Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Acinetobacter Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Bacterial Infections, Klebsiella pneumoniae Infections, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Mycobacterium Infections, Pseudomonas aeruginosa Infections and Tuberculosis.
Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)
- The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects
- The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
DNA Gyrase Subunit B (EC 5.99.1.3) - Overview
DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development
Abgentis Ltd
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Spero Therapeutics Inc
DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles
DS-11960558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-2969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GYR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Gyrase B and DNA Topoisomerase IV for Gram Negative Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-720 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Gyrase Subunit B (EC 5.99.1.3) - Dormant Products
DNA Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: Spero reports preliminary findings from phase 1 clinical trial of SPR720 and announces plans to advance program into proof-of-concept clinical trial in patients with NTM Pulmonary Disease
Nov 26, 2019: Spero Therapeutics provides new update on SPR720
Jun 17, 2019: Spero Therapeutics to present data for all pipeline programs including SPR-720 at the ASM Microbe 2019 Conference
Feb 26, 2019: Spero Therapeutics receives QIDP Designation from the U.S. FDA for the Development of SPR720
Jan 30, 2019: Spero starts Phase I trial of SPR720 for NTM infections
Nov 05, 2018: Spero Therapeutics announces positive results from SPR720 IND-Enabling studies and plans to initiate a phase 1 Trial
Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018
May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017
May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
DNA Gyrase Subunit B (EC 5.99.1.3) - Overview
DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development
Abgentis Ltd
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Spero Therapeutics Inc
DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles
DS-11960558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-2969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GYR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DNA Gyrase B and DNA Topoisomerase IV for Gram Negative Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-720 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNA Gyrase Subunit B (EC 5.99.1.3) - Dormant Products
DNA Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: Spero reports preliminary findings from phase 1 clinical trial of SPR720 and announces plans to advance program into proof-of-concept clinical trial in patients with NTM Pulmonary Disease
Nov 26, 2019: Spero Therapeutics provides new update on SPR720
Jun 17, 2019: Spero Therapeutics to present data for all pipeline programs including SPR-720 at the ASM Microbe 2019 Conference
Feb 26, 2019: Spero Therapeutics receives QIDP Designation from the U.S. FDA for the Development of SPR720
Jan 30, 2019: Spero starts Phase I trial of SPR720 for NTM infections
Nov 05, 2018: Spero Therapeutics announces positive results from SPR720 IND-Enabling studies and plans to initiate a phase 1 Trial
Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018
May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017
May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abgentis Ltd, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Spero Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abgentis Ltd, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Spero Therapeutics Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Abgentis Ltd
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Spero Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Abgentis Ltd
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Spero Therapeutics Inc
